Lofexidina (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Lofexidina" in Italian language version.

refsWebsite

Global rank Italian rank

13nih.gov

4^th place

9^th place

4oadoi.org

799^th place

22^nd place

4doi.org

2^nd place

7^th place

doi.org

dx.doi.org

Al-Ghananeem AM, Pharmacokinetics of lofexidine hydrochloride in healthy volunteers, in J Pharm Sci, vol. 98, n. 1, gennaio 2009, pp. 319–26, DOI:10.1002/jps.21401, PMID 18393298.
Al Ghananeem AM, Herman BH, Abbassi M, et al., Urine and plasma pharmacokinetics of lofexidine after oral delivery in opiate-dependent patients, in Am J Drug Alcohol Abuse, vol. 35, n. 5, 2009, pp. 311–5, DOI:10.1080/00952990903060135, PMID 19637105.
Yu E, Miotto K, Akerele E, et al., Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis, in Am J Drug Alcohol Abuse, vol. 34, n. 5, 2008, pp. 611–6, DOI:10.1080/00952990802308122, PMID 18821454.
Gish EC, Miller JL, Honey BL, Johnson PN, Lofexidine, an {alpha}2-receptor agonist for opioid detoxification, in Ann Pharmacother, vol. 44, n. 2, febbraio 2010, pp. 343–51, DOI:10.1345/aph.1M347, PMID 20040696.

nih.gov

ncbi.nlm.nih.gov

Jarrott B, Louis WJ, Summers RJ, The effect of a series of clonidine analogues on [3H] clonidine binding in rat cerebral cortex, in Biochem. Pharmacol., vol. 28, n. 1, 1979, pp. 141–4, PMID 215166.
Schultz HS, Chretien SD, Brewer DD, Eltorai MI, Weber MA, Centrally acting antihypertensive agents: a comparison of lofexidine with clonidine, in J Clin Pharmacol, vol. 21, n. 2, 1981, pp. 65–71, PMID 7229119.
Birch P, Clough DP, Hatton R, Wheatley DJ, Hypotensive and sedative properties of alpha-adrenoceptor agonists: relation to pre- and post-synaptic stimulation [proceedings], in Br. J. Pharmacol., vol. 68, n. 1, gennaio 1980, pp. 107P–108P, PMC 2044105, PMID 6101970.
Garrett BN, Kaplan NM, Lofexidine in the treatment of hypertension: a twice-daily versus one-daily dose comparison with 24-hour blood pressure monitoring, in J Clin Pharmacol, vol. 21, n. 4, aprile 1981, pp. 173–80, PMID 7016930.
Wilkins LH, Winternitz SR, Oparil S, Smith LR, Dustan HP, Lofexidine and clonidine in moderate essential hypertension, in Clin. Pharmacol. Ther., vol. 30, n. 6, dicembre 1981, pp. 752–07, PMID 7030578.
Al-Ghananeem AM, Pharmacokinetics of lofexidine hydrochloride in healthy volunteers, in J Pharm Sci, vol. 98, n. 1, gennaio 2009, pp. 319–26, DOI:10.1002/jps.21401, PMID 18393298.
Al Ghananeem AM, Herman BH, Abbassi M, et al., Urine and plasma pharmacokinetics of lofexidine after oral delivery in opiate-dependent patients, in Am J Drug Alcohol Abuse, vol. 35, n. 5, 2009, pp. 311–5, DOI:10.1080/00952990903060135, PMID 19637105.
Yu E, Miotto K, Akerele E, et al., Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis, in Am J Drug Alcohol Abuse, vol. 34, n. 5, 2008, pp. 611–6, DOI:10.1080/00952990802308122, PMID 18821454.
Tsai TH, Beitman RE, Gibson JP, Larson EJ, Friehe H, Fontaine R, Acute, subacute and chronic toxicity/Carcinogenicity of lofexidine, in Arzneimittelforschung, vol. 32, 8a, 1982, pp. 955–62, PMID 6890369.
Lofexidine, a clonidine analogue effective in opiate withdrawal, in Lancet, vol. 1, n. 8227, maggio 1981, pp. 991–2, PMID 6112397.
Gish EC, Miller JL, Honey BL, Johnson PN, Lofexidine, an {alpha}2-receptor agonist for opioid detoxification, in Ann Pharmacother, vol. 44, n. 2, febbraio 2010, pp. 343–51, DOI:10.1345/aph.1M347, PMID 20040696.
Washton AM, Resnick RB, Geyer G, Opiate withdrawal using lofexidine, a clonidine analogue with fewer side effects, in J Clin Psychiatry, vol. 44, n. 9, settembre 1983, pp. 335–7, PMID 6355070.
Kahn A, Mumford JP, Rogers GA, Beckford H, Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital, in Drug Alcohol Depend, vol. 44, n. 1, gennaio 1997, pp. 57–61, PMID 9031821.

oadoi.org

Al-Ghananeem AM, Pharmacokinetics of lofexidine hydrochloride in healthy volunteers, in J Pharm Sci, vol. 98, n. 1, gennaio 2009, pp. 319–26, DOI:10.1002/jps.21401, PMID 18393298.
Al Ghananeem AM, Herman BH, Abbassi M, et al., Urine and plasma pharmacokinetics of lofexidine after oral delivery in opiate-dependent patients, in Am J Drug Alcohol Abuse, vol. 35, n. 5, 2009, pp. 311–5, DOI:10.1080/00952990903060135, PMID 19637105.
Yu E, Miotto K, Akerele E, et al., Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis, in Am J Drug Alcohol Abuse, vol. 34, n. 5, 2008, pp. 611–6, DOI:10.1080/00952990802308122, PMID 18821454.
Gish EC, Miller JL, Honey BL, Johnson PN, Lofexidine, an {alpha}2-receptor agonist for opioid detoxification, in Ann Pharmacother, vol. 44, n. 2, febbraio 2010, pp. 343–51, DOI:10.1345/aph.1M347, PMID 20040696.